1324. Target Attainment of Exebacase, a First-In-Class Antibacterial Lysin, to Determine Optimal Doses for Adult Patients with Staphylococcus aureus (S. aureus) Bloodstream Infections (Bacteremia) Including Endocarditis

BACKGROUND: Exebacase, a novel, antibacterial direct lytic agent for the treatment of S. aureus bacterimia and endocarditis, studied in Phase 1 and 2 trials, demonstrated potential to improve clinical outcomes when used in addition to conventional antibiotics. Objectives were to develop population P...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghahramani, Parviz, Khariton, Tatiana, Chiu, Joannellyn, Cassino, Cara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776881/
http://dx.doi.org/10.1093/ofid/ofaa439.1506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776881/
http://dx.doi.org/10.1093/ofid/ofaa439.1506

Ejemplares similares